Karyopharm Therapeutics | KPTI - Assets


Karyopharm Therapeutics reported $108.42M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Abbott USD 110.43B 23.72B Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
AstraZeneca USD 114.02B 59M Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Eli Lilly USD 116.58B 4.1B Mar/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
GlaxoSmithKline GBP 62.87B 1.75B Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
J&J USD 200.89B 1.68B Mar/2026
Karyopharm Therapeutics USD 108.42M 12.18M Dec/2025
MacroGenics USD 217.87M 38.97M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Novartis USD 118.53B 7.58B Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Takeda JPY 15.45T 44.34B Mar/2026
Tectonic Therapeutic USD 246.58M 14.46M Mar/2026
TG Therapeutics USD 1.53B 465.58M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Xencor USD 736.85M 138.65M Mar/2026